CD8A and cancer: The immunogenic rejection of 3D cancer models is studied using the classic model of Ovalbumin-expressing mouse B16 melanoma (B16-OVA), which are challenged by OVA-specific CD8+ cytotoxic T lymphocytes (CTLs) bearing the OT-1 transgenic TCR (see “Methods”)15–19.